Onkologie. 2012:6(6):313-315
Gastric neuroendocrine neoplasms
- IV. interní klinika Všeobecná fakultní nemocnice a 1. lékařská fakulta UK, Praha
The paper presents recent opinions on gastric neuroendocrine neoplasms. This is a heterogeneus group including three types that distinguish
in their biological behaviour, and require different therapeutical approach. Type 1 arises in setting of chronic corporal atrophic
gastritis, malignant potential of this type is lower, this type 1 tumour may be treated with endoscopic removal of multiple small tumour
lesions. Gastric resection is indicated in larger lesions with infiltrative pattern of growth. Gastrectomy is rarely indicated. Type 2 arises as
consequence of Zollinger-Ellison syndrome. Both above-mentioned type are gastrin-dependent. Type 3 is a solitary, gastrin-independent
tumour with higher malignant potential. Surgery is treatment of choice, palliative therapy is indicated in advanced, generalized cases.
Keywords: gastric neuroendocrine neoplasms, gastrin, chromogranin A, grading
Published: December 1, 2012 Show citation
References
- Klimstra DS, Modlin IR, Coppola D, et al. The Pathologic Classification of Neuroendocrine Tumors. A review of Nomenclature, Grading, and Staging Systems. Consensus Guidelines for the Diagnosis and Management of Neuroendocrine Tumors 2010; 39(6): 707-712 NANETS (709).
Go to original source... 
Go to PubMed... - Ruszniewski P, Delle Fave G, Cadiot G, all other Frascati Consensus Conference participants. Well-Differentiated Gastric Tumors/Carcinomas: Neuroendocrinology 2006; 84(3): 158 - 164. Go to original source... Go to PubMed...
- Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology 2012; 95: 74-87. Go to original source... Go to PubMed...
- Beom SK, Yook JH, Kab Choong Kim, et al. Typical carcinoids and neuroendocrine carcinomas of the stomach: differing clinical courses and prognoses. The American Journal of Surgery 2010; 3: 328-333. Go to original source...
- Bordi C, D´Adda T, Azzoni C. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg 1995; 19(Suppl. 1): S8-19.
- Waldum HL, Sandvik AK, Idle JR. Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology 1998; 114: 1113-1115. Go to original source... Go to PubMed...
- Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S. Influence of multiple endocrine neoplasm type 1 on gastric endocrine cells in patients with Zollinger-Ellison syndrome. Gut 1992; 33: 1275-1279. Go to original source... Go to PubMed...
- Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology 2012; 95: 74-87. Go to original source... Go to PubMed...
- Granberg D, Wilander E, Stridsberg M, Granerus G, Skogseid B, Öberg K. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 1998; 43: 223-228. Go to original source... Go to PubMed...
- Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffin-like cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992; 102: 1409-1418. Go to original source...
- Fykse V, Sandvik AK, Qvigstad G, Falkmer GE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scandinavian Journal of Gastroenterology 2004; 39 (7): 621-628. Go to original source... Go to PubMed...
- Arnold R, Simon B, Wied M. Treatment of Neuroendocrine GEP Tumours with Somatostatin Analogues. Digestion 2000; 62 (Suppl. 1): 84-91. Go to original source... Go to PubMed...
- Khuroo MS, Khuroo MS, Khuroo NS. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. Journal of Gastroenterology and Hepatology 2010; 25(3): 548-554. Go to original source... Go to PubMed...
- Ferraro G, Annibale B, Marignani M, Azzoni C, D'Adda T, D'Ambra G, Bordi C, delle Fave G. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J Clin Endocrinol Metab 1996; 81(2): 677-683. Go to original source...
- Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. New England Journal of Medicine 2000; 343: 551-554. Go to original source... Go to PubMed...
- Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9(4): 261-267. Go to original source... Go to PubMed...
- Lewington WJ. Targeted radionuclide therapy for neuroendocrine tumour. Endocrine-Related Cancer 2003; 10: 497-501. Go to original source... Go to PubMed...